Thijs Cohen Tervaert

Junior Partner
Thijs Cohen Tervaert | Inkef
My journey

Thijs joined Inkef in 2016. Prior to Inkef, Thijs was a strategy consultant at the Boston Consulting Group with a focus on healthcare and technology. He worked on projects for pharmaceutical companies, hospitals and insurers across Europe. During a one year secondment, Thijs helped to establish a digital health incubator at the Amsterdam Health and Technology Institute in 2014. Thijs is a medical doctor and graduated at Leiden University. He has also co-authored several scientific papers. Thijs loves to skate, cycle, run and to spend weekends at the island of Vlieland.

One fact

I love to skate marathons and to spend time on the outdoor ice rink in the winter. Mastering your speed skating technique is a continuous process. Learning new ways to improve your balance, endurance, mental focus can all help to get into the ‘flow’. With my training buddies, I love to discuss how pros go about it and draw my inspiration from it.

Aidence | Inkef

Aidence is a company that is bringing the full potential of AI into the hands of medical professionals in medical imaging and disease detection. The company was acquired by RadNet in 2022.

Audion Therapeutics | Inkef

Audion Therapeutics is a private biopharmaceutical company dedicated to the discovery, development and commercialization of drugs and delivery technologies for the treatment of hearing loss.

Calypso Biotech | Inkef

Calypso Biotech is an immunotherapy biotech company, spin-off from Merck Serono, that discovers and develops monoclonal antibodies for the treatment of immune pathologies with large unmet medical needs. Calypso’s lead program, CALY-002, is a best-in-class therapeutic antibody against interleukin-15.

Castor | Inkef

Castor is a medical software development company based in Amsterdam, the Netherlands. Founded in 2011 by Derk Arts, their signature programme is a cloud-based electronic data capture platform which enables researchers to easily capture high-quality, reusable medical data.

TargED Biopharmaceuticals | Inkef

TargED Biopharmaceuticals B.V. is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis. Their technology using small antibodies to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis. The lead compound is currently under development for thrombotic thrombocytopenic purpura and Acute Ischemic Stroke.

ViCentra | Inkef

ViCentra has developed an insulin pump for diabetes patients. The company aims to create a user-friendly device designed to provide diabetes patients with greater freedom in their day-to-day lives.